Yannick Buccella, Gastrointestinal and Molecular Oncologist at City Hospital Zurich, shared FDA’s post on X, adding:
“Here we go! Early access protocol granted by the FDA for daraxonrasib!
It feels a bit like a historic day for the GI oncology community…”
Quoting FDA’s post:
“The FDA has issued a ‘safe to proceed’ letter allowing the initiation of an expanded access treatment protocol (EAP) for daraxonrasib, an experimental drug targeting pancreatic cancer.
Per EAP guidelines, requests must be submitted to the sponsor by U.S.-licensed physicians on behalf of eligible patients.”
Proceed to the video attached to the post.
You can also read: FDA Greenlit New Pancreatic Cancer Drug Daraxonrasib For Expanded Access
